![Opioid pills spilling out of medicine bottle with syringe next to it](https://www.uc.edu/news/articles/2023/04/n21161399/jcr:content/image.img.cq5dam.thumbnail.500.500.jpg/1680877082656.jpg)
WVXU: UC public health nursing expert sheds light on xylazine’s community impact
An animal tranquilizer, xylazine, has been increasingly found in illicit drugs and detected in overdose deaths across the country, sounding alarm bells at the local and federal levels. Tasha Turner-Bicknell, DNP, University of Cincinnati professor and public health nursing online programs director, served as a guest on WVXU's Cincinnati Edition to discuss the impacts and risks of xylazine.
Tasha Turner-Bicknell
Although not an opioid, xylazine can depress breathing, blood pressure, heart rate and body temperature to critical levels. And, because it is not an opioid, reversing an overdose caused by xylazine with naloxone can be more difficult; rescue breathing as part of CPR is needed, but people who use drugs often are wary of calling first responders, despite Good Samaritan laws in place.
"It is still hard to test for xylazine's presence in the body since the substance is not intended for human use. This makes it difficult to estimate how many overdose deaths can be attributed to xylazine," Turner-Bicknell said. "So, in the early days, people thought xylazine wasn’t present in their community."
Additionally, people who inject drugs containing xylazine can develop severe skin wounds and patches of dead tissue that easily become infected and, if left untreated, may lead to amputation. These wounds can develop in areas of the body away from the injection site and may become life-threatening.
"Providing basic medical care to people who use drugs is essential, or else these wounds will become worse and people will end up in the emergency room," Turner-Bicknell said. "And we know that the emergency room is not the ideal place for wound treatment."
Turner-Bicknell (left) in WVXU's studios as a guest on Cincinnati Edition.
As test strips for xylazine detection haven’t been approved for mass distribution and lawmakers work through the long process of classifying xylazine as a narcotic, the inclusion of wound care to avoid infections and more serious consequences in harm reduction outreach services is a step in the right direction.
And, while safe injection sites — which provide people who use drugs with a safe environment with access to health care and education — are an important factor in harm reduction, we will never have enough to be available for everyone, Turner-Bicknell said.
As a public health nurse, Turner-Bicknell has championed these kinds of harm reduction efforts. Her latest work focuses on increasing the implementation of harm reduction vending machines, providing safer smoking kits and developing mobile units as ways to extend community outreach to individuals previously not captured by existing harm reduction services, including people who smoke drugs, use stimulants or are unable or unwilling to attend syringe service programing.
Turner-Bicknell was selected present on this work at the 27th annual Harm Reduction International Conference, April 16-19 in Melbourne, Australia.
Listen to an audio recording of the March 27 Cincinnati Edition program at wvxu.org.
Learn More about UC's Public Health Nursing Online Programs
UC College of Nursing's Public Health Nursing online programs prepare you to respond to public health events with research-backed, population-based interventions and to lead and advance public health initiatives.
Learn more:
Related Stories
WVXU: UC public health nursing expert sheds light on xylazine’s community impact
April 6, 2023
University of Cincinnati professor and public health nursing programs director Tasha Turner-Bicknell joined WVXU’s Cincinnati Edition to discuss the impacts and risks of xylazine.
55KRC: Better student mental health resources needed
February 21, 2022
The University of Cincinnati's Dr. Erica Birkley was featured on 55KRC's Simply Medicine program to discuss the need for better mental health resources for students.
Healthline: COVID-19 increases risk of mental health disorders
February 21, 2022
The University of Cincinnati's Dr. Maria Espinola was featured in a Healthline article examining a recent study showing COVID-19 infection increases a person's risk for mental health disorders.
Reuters Health: Study examines psychotherapy's role in intervention for BPD
December 27, 2021
Reuters Health featured the University of Cincinnati's Dr. Maria Espinola in an article examining a recent study on the use of psychotherapy when treating young people with borderline personality disorder.
Everyday Health: COVID concerns versus Illness Anxiety Disorder
February 11, 2022
Everyday Health featured the University of Cincinnati's Dr. Shana Feibel in an article explaining the differences between being concerned and monitoring your health for COVID-19 and Illness Anxiety Disorder.
New summer program at CCM trains the voice, body and mind
January 24, 2022
Innovative voice instructor Taylor Stilson, LMT, CPT, MM is bringing a new summer program to uC's College-Conservatory of music in July 2022. The Stilson Institute at CCM trailblazes a new connection between historic voice pedagogy, modern sound-inspired modalities, science-based biomechanics and world-class faculty.
Reuters Health: RF ablation could be option for some thyroid cancers
February 17, 2022
Reuters Health featured the University of Cincinnati's Dr. Tammy Holm in an article examining the effectiveness of radiofrequency ablation to treat microscopic papillary thyroid cancers.
WVXU: Research aims to change effects of PTSD on brain
January 27, 2022
WVXU highlighted the work of University of Cincinnati professor Dr. Kate Chard at the Cincinnati VA, which involves cutting edge research and evidence-based treatments for veterans with post-traumatic stress disorder.
WFRV/HealthWatch: Lifting brain fog with virtual music therapy
December 14, 2021
The University of Cincinnati's Dr. Soma Sengupta was featured in WFRV's HealthWatch segment highlighting the pilot study of a music therapy app to help lift patients' brain fog.
CureToday: UC enrolling patients for glioblastoma trial
March 29, 2022
CureToday highlighted the University of Cincinnati's new glioblastoma immunotherapy trial in a recent article.